Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a phase 3 trial shows.

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Regeneron's chief scientific officer George Yancopoulos said that PN is an underdiagnosed disease with "immense physical and emotional burden for the 74,000 people in the US who are unable to ...

Patients with prurigo nodularis were randomly assigned to receive ... According to the presentation, all patients had a median disease duration of over 4 years and a mean Worst Itch Numerical ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN ... Data analysis included 204 patients, who had ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat a subset of adults with the rare disease hereditary transthyretin-mediated ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

Today marks World Rare Disease Day, which raises awareness about the different realities faced by many people in the world, the PN said. Every disease has its challenges. The rarer the disease ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

The PN said all those affected by a rare disease should be given the treatment directly for that disease, when possible, and all the psychological support necessary.

Data analysis included 204 patients, who had a median disease duration of 4-4.7 years ... safety of ruxolitinib cream in patients with prurigo nodularis: Results from a phase III, randomized ...